Prelude Therapeutics Ratios (2023-2026) | PRLD

Ratios Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026
Profitability
EBT Margin (Quarter) -1,145.87%-845.78%-314.12%-307.59%-309.54%
EBIT Margin (Quarter) -1,145.87%-845.78%-314.12%-307.59%-309.54%
EBITDA Margin (Quarter) -1,060.47%-721.58%-303.42%-291.68%-227.82%
Operating Margin (Quarter) -1,145.87%-845.78%-314.12%-307.59%-309.54%
Net Margin (Quarter) -1,145.87%-845.78%-314.12%-307.59%-309.54%
FCF Margin (Quarter) -911.97%-501.08%-294.08%409.91%-473.47%
Efficiency
Assets Average (Quarter) 262.39M235.70M210.76M186.37M158.39M128.09M104.84M118.03M130.48M
Equity Average (Quarter) 223.91M196.50M169.35M143.94M117.32M89.51M67.19M63.59M64.41M
Invested Capital (Quarter) 237.09M210.73M182.28M156.43M131.46M103.18M75.84M58.53M68.64M60.18M
Asset Utilization Ratio (Quarter) 0.130.140.13
Leverage & Solvency
Equity Ratio (Quarter) 0.850.850.810.790.750.730.660.620.490.50
Valuation
Enterprise Value (Quarter) -236.98M-205.97M-183.89M-157.67M-137.66M-103.12M-124.76M-58.19M-103.21M-144.60M
Return Ratios
Return on Sales (Quarter) -0.11%-0.08%-0.03%-0.03%-0.03%
Return on Capital Employed (Quarter) -86.93%-100.99%-125.96%-139.70%-160.77%-94.79%
Return on Assets (Quarter) -0.01%-0.01%-0.01%-0.01%-0.01%-0.01%-0.01%
Return on Equity (Quarter) -0.01%-0.01%-0.01%-0.02%-0.02%-0.02%-0.01%